Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ATF4 | P18848 | 12/20 | 0.58 |
| ▸ | LMNA | P02545 | 1/20 | 0.47 |
| ▸ | MEN1 | O00255 | 1/20 | 0.45 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.45 |
| ▸ | DRD2 | P14416 | 1/20 | 0.45 |
| ▸ | HPGD | P15428 | 1/20 | 0.45 |
| ▸ | HTT | P42858 | 1/20 | 0.45 |
| ▸ | RAB9A | P51151 | 1/20 | 0.45 |
| ▸ | ACACB | O00763 | 2/20 | 0.45 |
| ▸ | ACACA | Q13085 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28721546 | 1.00 | ATF4 (0.58) | ATF4LMNAMEN1KMT2ADRD2 | |
| SCHEMBL28521505 | 0.90 | ATF4 (0.64) | ATF4LMNAMEN1KMT2AHPGD | |
| SCHEMBL24225631 | 0.90 | ATF4 (0.64) | ATF4LMNAMEN1KMT2AHPGD | |
| SCHEMBL22777291 | 0.88 | ATF4 (0.67) | ATF4LMNAHPGDHTTRAB9A | |
| SCHEMBL22777288 | 0.88 | ATF4 (0.67) | ATF4LMNAHPGDHTTRAB9A | |
| SCHEMBL22777540 | 0.87 | ATF4 (0.66) | ATF4LMNAMEN1KMT2AHPGD | |
| SCHEMBL22373833 | 0.87 | ATF4 (0.49) | ATF4DRD2 | |
| SCHEMBL22373784 | 0.86 | ATF4 (0.59) | ATF4LMNAMEN1KMT2AHPGD | |
| SCHEMBL22373886 | 0.86 | ATF4 (0.59) | ATF4LMNAMEN1KMT2AHPGD | |
| SCHEMBL23920510 | 0.86 | ATF4 (0.66) | ATF4LMNAKMT2AACACBACACA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3983378-A1 | INHIBITORS OF INTEGRATED STRESS RESPONSE PATHWAY | Praxis Biotech LLC (US) | 2022-04-20 | — | — | EP | disclosed |
| CN-114206829-A | Integrated stress response pathway inhibitors | 普拉西斯生物技术有限责任公司 | 2022-03-18 | — | — | CN | disclosed |
| US-20210317102-A1 | INHIBITORS OF INTEGRATED STRESS RESPONSE PATHWAY | ALTOS LABS, INC. | 2021-10-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210317102-A1 | INHIBITORS OF INTEGRATED STRESS RESPONSE PATHWAY | ATF4, DDIT3, ATF1 | ATF4 1/4885LMNA 4459/4885MEN1 4345/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.